BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
PRODID:-//Telerik Inc.//Sitefinity CMS 15.4//EN
BEGIN:VEVENT
DESCRIPTION:This 1-day scientific meeting will provide an update on latest 
 trends in HTA\, including: the Real-World Evidence Navigator tool created 
 by the IMI GetReal project\; the EUnetHTA Joint Action 3 initiative and me
 thodology being researched\; introduction to value-based frameworks and es
 timands in HTA.&nbsp\; Patient perspectives in HTA will be discussed inclu
 ding how to involve patients in HTA and latest methods in patient reported
  outcomes.&nbsp\; HTA related methodological considerations will be highli
 ghted including approaches to handle treatment switching in HTA.&nbsp\; In
 dustry HTA case studies will also be presented.&nbsp\; Speakers include we
 ll known representatives from academia\, European regulatory bodies and in
 dustry. The day will end with a panel discussion. \nTo download the flyer 
 please click here. Outline of the Agenda      &nbsp\;09:30 Welcome Chrissi
 e Fletcher (Amgen\, Chair HTA SIG)\, William Malbecq (MSD)\n            &n
 bsp\;   &nbsp\;09:50 Session: Trends in HTA(1)  Introducing the RWE Naviga
 tor&nbsp\;-&nbsp\;Heather Stegenga (NICE)  EUnetHTA Joint Action 3 activit
 ies&nbsp\;- Zoe Garrett (NICE)    &nbsp\;11:10 Coffee Break   &nbsp\;11:30
  Session: HTA research and methods  Adjusting for treatment switching in r
 andomised controlled trials&nbsp\;- Nick Latimer (University of Sheffield)
    Accumulated Industry experience in bridging regulatory and HTA&nbsp\;re
 search methodologies&nbsp\;-&nbsp\;William Malbecq\, Kristel Vandormael (M
 SD)    &nbsp\;12:50 &nbsp\;Lunch   &nbsp\;13:30 Session: Patient perspecti
 ves in HTA  Involving the patient in HTA&nbsp\;-&nbsp\;Karen Facey (Eviden
 ce Based Health Policy Consultant)   Benefit-risk Assessment in HTA&nbsp\;
 -&nbsp\;Shahrul Mt-Isa (MSD)\, Susan Talbot (Amgen)    &nbsp\;14:50 Coffee
  Break    &nbsp\;15:10 Session: Trends in HTA(2)  Value-based frameworks&n
 bsp\;-&nbsp\;Jan McKendrick (PRMA Consulting)  Estimands in HTA-&nbsp\;Jas
 on Wang (Celgene)\,&nbsp\;Chrissie Fletcher (Amgen)     &nbsp\;16:30 Panel
  Discussion   &nbsp\;17:00 Summary and meeting close      Registration \nF
 ee includes lunch &amp\; refreshments.     Registration on or before 14th 
 October   PSI Member &nbsp\;&pound\;100 (plus VAT)   Non-Member &nbsp\;&po
 und\;140&nbsp\;(plus VAT)    Academic &nbsp\;&pound\;70 (plus VAT)   Regis
 tration after 14th October   PSI Member &nbsp\;&pound\;120 (plus VAT)   No
 n-Member &nbsp\;&pound\;160 (plus VAT)   Academic &nbsp\;&pound\;90 (plus 
 VAT)    \nRegistration is now closed.
DTEND;VALUE=DATE:20171129
DTSTAMP:20260913T052941Z
DTSTART;VALUE=DATE:20171128
LOCATION:N1C 4AG\,London\,Two Pancras Square\,MSD 
SEQUENCE:0
SUMMARY:European Statistical Meeting: Latest Trends in Health Technology As
 sessments
UID:RFCALITEM639248741812381019
X-ALT-DESC;FMTTYPE=text/html:<p>This 1-day scientific meeting will provide 
 an update on latest trends in HTA\, including: the Real-World Evidence Nav
 igator tool created by the IMI GetReal project\; the EUnetHTA Joint Action
  3 initiative and methodology being researched\; introduction to value-bas
 ed frameworks and estimands in HTA.&nbsp\; Patient perspectives in HTA wil
 l be discussed including how to involve patients in HTA and latest methods
  in patient reported outcomes.&nbsp\; HTA related methodological considera
 tions will be highlighted including approaches to handle treatment switchi
 ng in HTA.&nbsp\; Industry HTA case studies will also be presented.&nbsp\;
 </p> <p>Speakers include well known representatives from academia\, Europe
 an regulatory bodies and industry. The day will end with a panel discussio
 n.<br /> <br />\nTo download the flyer please <a href="https://www.psiweb.
 org/docs/default-source/default-document-library/psi_efspi-hta-flyer-2017-
 version26sept17.pdf?sfvrsn=b9dcdb_0&sf_site_temp=true&sf_site=00000000-000
 0-0000-0000-000000000000" title="PSI_EFSPI HTA Flyer 2017 Version26Sept17"
 >click here</a>.</p> <strong><span style="text-decoration: underline\;">Ou
 tline of the Agenda<br /> </span></strong><br /> <strong><span style="text
 -decoration: underline\;"></span></strong> <table> <tbody> <tr> <td>&nbsp\
 ;09:30</td> <td><strong>Welcome<br /> </strong>Chrissie Fletcher (Amgen\, 
 Chair HTA SIG)\, William Malbecq (MSD)<br />\n            &nbsp\;</td> </t
 r> <tr> <td>&nbsp\;09:50</td> <td><strong>Session: Trends in HTA(1)<br /> 
 <br /> </strong><em><em><a href="https://www.psiweb.org/docs/default-sourc
 e/default-document-library/heather-stegenga-(nice).pdf?sfvrsn=3abdfdb_0&sf
 _site_temp=true&sf_site=00000000-0000-0000-0000-000000000000" title="Intro
 ducing the RWE Navigator">Introducing the RWE Navigator</a>&nbsp\;-&nbsp\;
 Heather Stegenga (NICE)<br /> <br /> <em><a href="https://www.psiweb.org/d
 ocs/default-source/default-document-library/zoe-garrett-(nice).pdf?sfvrsn=
 15abdfdb_0&sf_site_temp=true&sf_site=00000000-0000-0000-0000-000000000000"
  title="EUnetHTA Joint Action 3 activities">EUnetHTA Joint Action 3 activi
 ties</a>&nbsp\;- Zoe Garrett (NICE)</em></em><br /> </em></td> </tr> <tr> 
 <td>&nbsp\;11:10</td> <td><strong>Coffee Break</strong></td> </tr> <tr> <t
 d>&nbsp\;11:30</td> <td><strong>Session: HTA research and methods<br /> </
 strong><em><br /> <a href="https://www.psiweb.org/docs/default-source/defa
 ult-document-library/nick-latimer-(university-of-sheffield).pdf?sfvrsn=1fa
 bdfdb_0&sf_site_temp=true&sf_site=00000000-0000-0000-0000-000000000000" ti
 tle="Adjusting for treatment switching in randomised controlled trials">Ad
 justing for treatment switching in randomised controlled trials</a>&nbsp\;
 - Nick Latimer (University of Sheffield)<br /> <br /> </em> <div><em><em><
 a href="https://www.psiweb.org/docs/default-source/default-document-librar
 y/william-malbecq-(msd).pdf?sfvrsn=cf53dfdb_0&sf_site_temp=true&sf_site=00
 000000-0000-0000-0000-000000000000">Accumulated Industry experience in bri
 dging regulatory and HTA&nbsp\;<em>research methodologies</em></a>&nbsp\;-
 &nbsp\;William Malbecq\, Kristel Vandormael (MSD)</em></em></div> </td> </
 tr> <tr> <td>&nbsp\;12:50</td> <td>&nbsp\;<strong>Lunch</strong></td> </tr
 > <tr> <td>&nbsp\;13:30</td> <td><strong>Session: Patient perspectives in 
 HTA<br /> </strong><br /> <em><a href="https://www.psiweb.org/docs/default
 -source/default-document-library/karen-facey-(evidence-based-health-policy
 -consultant).pdf?sfvrsn=20abdfdb_0&sf_site_temp=true&sf_site=00000000-0000
 -0000-0000-000000000000" title="Involving the patient in HTA">Involving th
 e patient in HTA</a>&nbsp\;-&nbsp\;Karen Facey (Evidence Based Health Poli
 cy Consultant)<br /> <br /> </em> <div><em><a href="https://www.psiweb.org
 /docs/default-source/default-document-library/shahrul-mt-isa-(msd).pdf?sfv
 rsn=d153dfdb_0&sf_site_temp=true&sf_site=00000000-0000-0000-0000-000000000
 000" title="Benefit-risk Assessment in HTA">Benefit-risk Assessment in HTA
 </a>&nbsp\;-&nbsp\;Shahrul Mt-Isa (MSD)\, Susan Talbot (Amgen)</em></div> 
 </td> </tr> <tr> <td>&nbsp\;14:50</td> <td><strong>Coffee Break</strong><b
 r /> </td> </tr> <tr> <td>&nbsp\;15:10</td> <td><strong>Session: Trends in
  HTA(2)<br /> </strong><br /> <em><a href="https://www.psiweb.org/docs/def
 ault-source/default-document-library/jan-mckendrick-(prma-consulting).pdf?
 sfvrsn=2aabdfdb_0&sf_site_temp=true&sf_site=00000000-0000-0000-0000-000000
 000000" title="Value-based frameworks">Value-based frameworks</a>&nbsp\;-&
 nbsp\;Jan McKendrick (PRMA Consulting)<br /> </em><br /> <em><a href="http
 s://www.psiweb.org/docs/default-source/default-document-library/jason-wang
 -(celgene).pdf?sfvrsn=3cabdfdb_0&sf_site_temp=true&sf_site=00000000-0000-0
 000-0000-000000000000" title="Estimands in HTA">Estimands in HTA</a>-&nbsp
 \;Jason Wang (Celgene)\,&nbsp\;Chrissie Fletcher (Amgen)<br /> </em><br />
  </td> </tr> <tr> <td>&nbsp\;16:30</td> <td><strong>Panel Discussion</stro
 ng></td> </tr> <tr> <td>&nbsp\;17:00</td> <td><strong>Summary and meeting 
 close</strong><br /> </td> </tr> </tbody> </table> <br /> <strong><span st
 yle="text-decoration: underline\;">Registration<br /> </span></strong><br 
 />\nFee includes lunch &amp\; refreshments.<strong><span style="text-decor
 ation: underline\;"><br /> </span></strong><br /> <table class="PSI-defaul
 t-table"> <tbody> <tr class="PSI-default-tableTableHeaderRow"> <td colspan
 ="2" class="PSI-default-tableTableHeaderFirstCol">Registration on or befor
 e 14th October</td> </tr> <tr class="PSI-default-tableTableOddRow"> <td cl
 ass="PSI-default-tableTableFirstCol">PSI Member</td> <td class="PSI-defaul
 t-tableTableOddCol">&nbsp\;&pound\;100 (plus VAT)</td> </tr> <tr class="PS
 I-default-tableTableEvenRow"> <td class="PSI-default-tableTableFirstCol">N
 on-Member</td> <td class="PSI-default-tableTableOddCol">&nbsp\;&pound\;140
 &nbsp\;(plus VAT)<br /> </td> </tr> <tr class="PSI-default-tableTableOddRo
 w"> <td class="PSI-default-tableTableFirstCol">Academic</td> <td class="PS
 I-default-tableTableOddCol">&nbsp\;&pound\;70 (plus VAT)</td> </tr> <tr cl
 ass="PSI-default-tableTableEvenRow"> <td colspan="2" class="PSI-default-ta
 bleTableFirstCol" style="background-color: #005a84\;"><strong><span style=
 "color: #ffffff\;">Registration after 14th October</span></strong></td> </
 tr> <tr class="PSI-default-tableTableOddRow"> <td class="PSI-default-table
 TableFirstCol">PSI Member</td> <td class="PSI-default-tableTableOddCol">&n
 bsp\;&pound\;120 (plus VAT)</td> </tr> <tr class="PSI-default-tableTableEv
 enRow"> <td class="PSI-default-tableTableFirstCol">Non-Member</td> <td cla
 ss="PSI-default-tableTableOddCol">&nbsp\;&pound\;160 (plus VAT)</td> </tr>
  <tr class="PSI-default-tableTableOddRow"> <td class="PSI-default-tableTab
 leFirstCol">Academic</td> <td class="PSI-default-tableTableOddCol">&nbsp\;
 &pound\;90 (plus VAT)</td> </tr> </tbody> </table> <br />\nRegistration is
  now closed.
END:VEVENT
END:VCALENDAR